Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
7.66
+0.12 (1.59%)
Oct 12, 2026, 11:47 AM EDT - Market open
Ocular Therapeutix Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Ocular Therapeutix stock has a consensus rating of "Strong Buy" and an average price target of $26. The average 1-year stock price forecast is 239.43% higher than the current stock price, while the lowest is $14 (+82.77%) and the highest is $34 (+343.86%).
Price Target: $26 (+239.43%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ocular Therapeutix stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 8 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $31 | Buy | Maintains | $31 | +304.70% | Oct 12, 2026 |
| UBS No rating | UBS | Buy Initiates $14 | Buy | Initiates | $14 | +82.77% | Oct 11, 2026 |
| Needham | Needham | Buy Maintains $18 | Buy | Maintains | $18 | +134.99% | Sep 28, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 25, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +226.37% | Sep 16, 2026 |
Financial Forecast
Revenue This Year
52.84M
from 51.95M
Increased by 1.70%
Revenue Next Year
102.04M
from 52.84M
Increased by 93.13%
EPS This Year
-1.44
from -1.42
EPS Next Year
-1.48
from -1.44
EPS and Forward PE are based on non-GAAP adjusted numbers.